Following on from yesterday’s update on how proteomics and genomics can help us make better decisions in breast cancer at the Miami Breast Cancer Conference (#MBCC14) organised by PER, today also looks at the complexity of genomics, but from a different lens – can genomics impact the way we actually treat patients?

Interestingly, last week there was a rumour (unconfirmed) that Dr Debu Tripathy (UCLA) was heading to MD Anderson to head up the breast cancer division following Gabriel Hortobaygi’s retirement. That move was confirmed yesterday, with a tweet from Dr Naoto Ueno, who is part of the group:

His talk on the increasing role of genomics in breast cancer on Friday was engaging, thoughtful and well delivered.

It also made me (and several others) stop and think.

To find out why, you can sign in or sign up below.

 MBCC: Will NGS change the way we treat metastatic breast cancer?

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $369 for 3 months access (does not auto renew), $598 for 6 months access (does not auto renew) and $997 for 12 months access (does not auto renew). Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals contained within it.